Diffuse Alveolar Hemorrhage after Adalimumab Treatment of Rheumatoid Arthritis.
- Author:
Hye Jin KIM
1
;
Hong Sung CHOUGH
;
Yun Sung KIM
;
Hyun Sook KIM
Author Information
1. Department of Internal Medicine, Soonchunhyang University College of Medicine, Seoul, Korea. healthyra@schmc.ac.kr
- Publication Type:Case Report
- Keywords:
Alveolar hemorrhage;
Adalimumab;
Rheumatoid arthritis
- MeSH:
Antibodies, Monoclonal, Humanized;
Arthritis, Rheumatoid;
Connective Tissue;
Fever;
Hemoptysis;
Hemorrhage;
Humans;
Microvessels;
Respiratory Insufficiency;
Adalimumab
- From:Korean Journal of Medicine
2013;85(4):439-444
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Diffuse alveolar hemorrhage (DAH) is a life-threatening condition involving hemorrhage originating in the pulmonary microvasculature. The clinical syndrome is characterized by hemoptysis, hypoxemic respiratory failure, low-grade fever, and diffuse pulmonary infiltrates. The majority of cases of DAH are caused by pulmonary renal syndromes, connective tissue disorders, and drugs. Here, we present a case of DAH associated with adalimumab treatment in a patient with rheumatoid arthritis.
